ClinicaliQ Trial Snapshot
- Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib — Active Not Recruiting • Phase III • Oncology • NCT04421963.
- Patients benefiting from olaparib in previous cancer trials can continue receiving it under this extension study.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The rationale of the ROSY-O study is to continue to provide study treatment for patients who have participated in a parent study with olaparib and who are continuing to derive clinical benefit from treatment at the end of such studies, as judged by the Investigator. Conditions: Ovarian Cancer, Breast Cancer Interventions: Olaparib Lead Sponsor: AstraZeneca Planned Enrollment: 185 participants